MRI测量的左心室质量与心血管事件的长期风险:动脉粥样硬化多种族研究(MESA)
基于MESA前瞻性多种族队列,4988名基线无临床心血管疾病的参与者经心脏MRI测量左心室质量并随访15年,左心室肥厚是硬性冠心病事件、心肌梗死、冠心病死亡、其他心血管死亡和心力衰竭的独立预测因子,且对冠心病死亡、其他心血管死亡和心衰的预测能力强于冠状动脉钙化评分。
要点
- 心脏MRI测得的左心室肥厚可独立预测15年硬性冠心病事件、心肌梗死、冠心病死亡、其他心血管死亡和心衰。
- 左心室肥厚对冠心病死亡、其他心血管死亡和心衰的预测能力强于冠状动脉钙化评分。
- 左心室肥厚者心血管事件风险升高,尤其随访5年后更明显。
核心结论
- 左心室质量升高与15年随访中的硬性冠心病事件、其他心血管死亡和心力衰竭强烈相关,且独立于传统危险因素和冠状动脉钙化评分。
研究设计与样本
- MESA为美国正在进行的前瞻性多中心人群-based研究(ClinicalTrials.gov:NCT00005487)。
- 2000年至2002年共纳入6814名基线无临床心血管疾病、年龄45-84岁的参与者。
- 4988名参与者(2613名女性[52.4%];平均年龄62岁±10.1[标准差])随访15年心血管事件,基线心脏MRI左心室质量由中心核心实验室半自动化软件得出。
- 采用Cox比例风险模型、Kaplan-Meier曲线和z评分评估左心室肥厚的影响。
诊断标准与关键数值
- 左心室肥厚预测硬性冠心病事件HR 2.7(95%CI:1.9,3.8)、心肌梗死HR 2.8(95%CI:1.8,4.0)、冠心病死亡HR 4.3(95%CI:2.5,7.3)、其他心血管死亡HR 7.5(95%CI:4.2,13.5)、心力衰竭HR 5.4(95%CI:3.8,7.5),所有终点P < .001。
- 左心室肥厚对冠心病死亡、其他心血管死亡和心力衰竭的预测强于冠状动脉钙化评分,z评分分别为5.4 vs 3.4、6.8 vs 2.4、9.7 vs 3.2(左心室肥厚 vs 冠状动脉钙化评分)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Few data exist on the long-term risk prediction of elevated left ventricular (LV) mass quantified by MRI for cardiovascular (CV) events in a contemporary, ethnically diverse cohort. Purpose To assess the long-term impact of elevated LV mass on CV events in a prospective cohort study of a multiethnic population in relationship to risk factors and coronary artery calcium (CAC) score. Materials and Methods The Multi-Ethnic Study of Atherosclerosis, or MESA (ClinicalTrials.gov: NCT00005487), is an ongoing prospective multicenter population-based study in the United States. A total of 6814 participants (age range, 45-84 years) free of clinical CV disease at baseline were enrolled between 2000 and 2002. In 4988 participants (2613 [52.4%] women; mean age, 62 years ± 10.1 [standard deviation]) followed over 15 years for CV events, LV mass was derived from cardiac MRI at baseline enrollment by using semiautomated software at a central core laboratory. Cox proportional hazard models, Kaplan-Meier curves, and z scores were applied to assess the impact of LV hypertrophy. Results A total of 290 participants had hard coronary heart disease (CHD) events (207 myocardial infarctions [MIs], 95 CHD deaths), 57 had other CV disease-related deaths, and 215 had heart failure (HF). LV hypertrophy was an independent predictor of hard CHD events (hazard ratio [HR]: 2.7; 95% confidence interval [CI]: 1.9, 3.8), MI (HR: 2.8; 95% CI: 1.8, 4.0), CHD death (HR: 4.3; 95% CI: 2.5, 7.3), other CV death (HR: 7.5; 95% CI: 4.2, 13.5), and HF (HR: 5.4; 95% CI: 3.8, 7.5) (P < .001 for all end points). LV hypertrophy was a stronger predictor than CAC for CHD death, other CV death, and HF (z scores: 5.4 vs 3.4, 6.8 vs 2.4, and 9.7 vs 3.2 for LV hypertrophy vs CAC, respectively). Kaplan-Meier analysis demonstrated an increased risk of CV events in participants with LV hypertrophy, particularly after 5 years. Conclusion Elevated left ventricular mass was strongly associated with hard coronary heart disease events, other cardiovascular death, and heart failure over 15 years of follow-up, independent of traditional risk factors and coronary artery calcium score. © RSNA, 2019 See also the editorial by Hanneman in this issue.
引用
- Kawel-Boehm N, Kronmal R, Eng J, et al. Left Ventricular Mass at MRI and Long-term Risk of Cardiovascular Events: The Multi-Ethnic Study of Atherosclerosis (MESA). Radiology. 2019. PMID: 31453766. doi:10.1148/radiol.2019182871
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。